MENU
HYPD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

HYPD stock forecast, quote, news & analysis

Hyperion DeFi Inc is a USA-based company building a long-term strategic treasury of Hyperliquid's native token, HYPE... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Nov 07, 2026

Why Hyperion DeFi (HYPD) Stock Is Down -26% in the Last 30 Days

Key Takeaways

  • Hyperion DeFi (HYPD) shares fell about 26% over the past 30 days, sliding from roughly $3.37 on October 8 to $2.49 by the November 6 close.
  • The decline closely tracks weakness in HYPE, the native token of the Hyperliquid blockchain, which anchors the company's treasury value and net asset value.
  • Sentiment turned after U.S. midterm results clouded the outlook for digital-asset policy, prompting profit-taking from a sharp late-September rally.
  • Over the full quarter the stock is roughly flat to modestly lower, even after a guidance raise, a $20 million buyback, and full retirement of legacy debt.
  • Hyperion DeFi is scheduled to report third-quarter results on November 12, 2026, with HYPE price action and the discount to net asset value in focus.
  • For additional detail, review Hyperion DeFi's Price Targets, Earnings history, and Forecast on dedicated pages.
  • Explore Trending AI Robots to see AI-driven trading strategies across thousands of tickers.

Hyperion DeFi (HYPD) Company Overview and Market Position

Hyperion DeFi, Inc. (NASDAQ: HYPD) is the first U.S. publicly listed company building on Hyperliquid, a layer-one blockchain optimized for high-frequency, onchain trading. The company operates through two segments: a Digital Assets segment centered on a long-term strategic treasury of HYPE, Hyperliquid's native token, and an Ophthalmic Technology segment developing the Optejet device, a legacy of its former identity as Eyenovia.

The Digital Assets business is the primary focus for investors. By holding HYPE and earning staking yield and other DeFi income, Hyperion DeFi offers public-market investors simplified exposure to the Hyperliquid ecosystem. As a result, the stock behaves in large part as a proxy for HYPE and Hyperliquid's growth, tying its share price closely to token-market sentiment.

Hyperion DeFi (HYPD) Stock Price Performance: Last 30 Days vs. Quarter

Over the past 30 days, HYPD fell roughly 26%, from a closing price of about $3.37 on October 8 to $2.49 on November 6. The decline accelerated in the final sessions of the period, with the stock dropping from about $3.07 on November 4 to $2.49 just two sessions later.

The longer-term picture is more nuanced. The stock began the quarter near $2.70 in early August, climbed to a closing high of about $4.17 on September 24, and then surrendered most of those gains. Measured from early August to early November, HYPD is down roughly 8%, but the round-trip reflects unusually high volatility rather than a one-way trend. A 52-week range of roughly $2.34 to $6.48 underscores the stock's wide swings.

What Drove HYPD Stock Price in the Last 30 Days

The primary catalyst behind the recent decline was weakness in HYPE, the token that anchors Hyperion DeFi's treasury. Because a substantial portion of the company's value is tied to its HYPE holdings, a falling token price directly reduces the market's assessment of the company's net asset value.

Sentiment around digital assets deteriorated after the U.S. midterm elections, when the outcome raised uncertainty about the pace of crypto-friendly regulation and the potential onshoring of offshore decentralized exchanges such as Hyperliquid. Onchain observers also noted large HYPE transfers from wallets linked to major venture investors to exchanges beginning in late October, adding to downward pressure.

These macro and token-market forces combined with profit-taking after a strong September run and the stock's inherently thin liquidity. With a beta near 2.7 and a relatively small float, HYPD tends to amplify both rallies and selloffs, which helps explain the sharp two-day slide in early November.

What Drove HYPD Stock Performance Over the Last Quarter

The quarter reflects strong company-level execution meeting a cooling crypto market. In September, Hyperion DeFi raised its full-year 2026 guidance, announced a $20 million share-repurchase program, and unveiled the first institutional credit facility on Hyperliquid alongside Anchorage Digital and HyperLend. In early October, the company repurchased shares and fully retired its roughly $8.6 million in legacy debt, leaving no long-term debt outstanding.

Those developments fueled the rally toward $4.17 in late September. But as HYPE pulled back and policy expectations shifted, the stock relinquished the gains. The net result was a quarter that was roughly flat to slightly negative despite a fundamentally improved balance sheet, illustrating how tightly HYPD's share price is linked to token-market conditions rather than only to its own operating news.

Trending AI Robots

Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a platform that offers hundreds of bots trading thousands of tickers. Only top-performing and most relevant bots appear in this section, giving visitors a focused view of strategies that have recently stood out. The bots vary in strategy, timeframe, and performance metrics, so the section reflects a range of approaches rather than a single trading style. It is designed as a discovery tool for those interested in algorithmic and data-driven trading ideas. To see which automated strategies are currently gaining attention, visit the Trending AI Robots page.

HYPD Stock Forecast Drivers: What Investors Should Watch Next

Investors will focus first on third-quarter results, scheduled for November 12, 2026, and management's updated outlook on adjusted gross profit and cash flow. The most important external variable remains the price of HYPE and broader activity on the Hyperliquid network, since these drive the company's treasury value and staking yield.

Other factors to monitor include the regulatory environment for digital assets and decentralized exchanges, the company's progress in narrowing the gap between its share price and net asset value, and any further capital-allocation actions such as buybacks or treasury management. As of early November, available market data showed a "Strong Buy" consensus among a small group of analysts with an average 12-month price target near $9.80, though such targets reflect analyst views rather than guaranteed outcomes. Given the stock's high volatility and crypto-linked business model, wide price swings may persist.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for HYPD with price predictions
Nov 10, 2026

HYPD in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026

HYPD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 34 cases where HYPD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HYPD's RSI Oscillator exited the oversold zone, 23 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where HYPD advanced for three days, in 186 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HYPD as a result. In 70 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for HYPD turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 38 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

HYPD moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for HYPD crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

The 50-day moving average for HYPD moved below the 200-day moving average on November 10, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HYPD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for HYPD entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.380) is normal, around the industry mean (3.498). P/E Ratio (-0.664) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (25.707) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. HYPD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HYPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 5%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was -13%. LABT experienced the highest price growth at 113%, while KPTI experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was 12% and the average quarterly volume growth was -27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company which delivers sight saving therapies

Industry Biotechnology

Industry
Pharmaceuticals Major
Address
23461 South Point Drive
Phone
+1 833 393-6684
Employees
9
Web
https://www.hyperiondefi.com
Why Hyperion DeFi (HYPD) Stock Is Down -26% in the Last 30 Days